Basal kinomic activity profiles.

<p>Unsupervised hierarchical clustering of basal (untreated) tyrosine kinomic profiles displaying log transformed slope-exposure for (<b>A</b>) all 144 peptides and (<b>B</b>) as change from sample mean and filtered for variance >1. Red in (A) indicates relative increased signal and in (B) indicates an increase from sample mean. Blue indicates the opposite. Blue arrowhead points to red line denoting dendrogram separation. (<b>C</b>) Western blotting of GAPDH and Actin is shown with sample concentration indicated for each patient.</p

CONSORT diagram on patient enrollment.

<p>CONSORT diagram on patient enrollment.</p

Survival Curves for age-adjusted Cox Proportional Hazard models for 1^st quartile (red) and 3^rd quartile (blue) gene expression values for each gene in the Proneural subtype.

<p>Survival Curves for age-adjusted Cox Proportional Hazard models for 1^st quartile (red) and 3^rd quartile (blue) gene expression values for each gene in the Proneural subtype.</p

Kinomic platform and Electromagnetic Navigation Bronchoscopy.

<p>(A) Overall experimental flow with a (B) Representative in-procedure display of ENB and a schematic of PamChip assay used to measure basal kinomic activity displayed as (C) raw array picture of the 144 phosphorylatable peptides and (D) phosphorylation changes with drug treatment displayed with illustration of comparative fluorescent detection below.</p

Multi-gene Cox Proportional Hazards models for all samples and specific subtypes using three different model selection methods: Stepwise regression with age as a covariate (SW with age), stepwise regression without age (SW no age), and Elastic Net.

<p>Hazard ratios with confidence limits are given for each term added to each model. If the term was not added to a given model, NI is displayed for “not included”. The total explained variance for each model (R²) is also displayed.</p

Patient characteristics and tumor evaluation.

<p>M-male; F-female; NSCLC-non small cell lung cancer; MD-PD-moderately differentiated to poorly differentiated; SBRT-stereotactic body radiotherapy.</p><p>Patient characteristics and tumor evaluation.</p

<i>Ex vivo</i> drug response profile.

<p>Displays <i>ex</i><i>vivo</i> drug response profiles as (A) a heatmap of kinase activity (log signal values) change from untreated, clustered by row, of altered phosphopeptides per patient, per dose at 20 nM, 0.5 µM or 20 µM. (B) <i>Ex vivo</i> prewash kinetic peptide phosphorylation (y axis per cell) over time (x axis per cell) of selected peptides in the selected samples, in response to indicated drugs at 20 µM. Blue lines denote untreated, and green lines indicate treated phosphorylation curves.</p

Graph of predicted and actual survival times in Proneural subtype for the discovery data set (left) and the validation data set (right) using the age-adjusted stepwise selection model (up to IFI44).

<p>The correlation between predicted and actual survival values is 0.64 (0.45, 0.77) in the discovery set and 0.39 (0.16, 0.57) in validation set.</p

Functional Annotation networks from IPA (Ingenuity Pathway Analysis) that show documented gene relationships among the genes in the hypothesized eight gene STAT1/IFN gene set (A) and that show the functional relationships among these genes as they relate to Interferon signaling (B) (genes in eight gene signature are shaded).

<p>Functional Annotation networks from IPA (Ingenuity Pathway Analysis) that show documented gene relationships among the genes in the hypothesized eight gene STAT1/IFN gene set (A) and that show the functional relationships among these genes as they relate to Interferon signaling (B) (genes in eight gene signature are shaded).</p

Bar plot of total explained variance (R²) for survival models discovered using stepwise selection with genes only (“No Age”) or with genes and age (“Age”) for all GBM patients and by subtype.

<p>Bar plot of total explained variance (R²) for survival models discovered using stepwise selection with genes only (“No Age”) or with genes and age (“Age”) for all GBM patients and by subtype.</p